Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

AVIR
Atea Pharmaceuticals, Inc. Common Stock
stock NASDAQ

At Close
Jul 31, 2026 3:59:45 PM EDT
4.70USD-0.949%(-0.04)471,928
3.03Bid   5.89Ask   2.86Spread
Pre-market
Jul 29, 2026 9:26:30 AM EDT
4.43USD-4.089%(-0.19)0
After-hours
Jul 31, 2026 4:00:30 PM EDT
4.70USD+0.106%(0.00)65,881
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 23, 2022
01:12PM EST  Pomerantz LLP is investigating claims on behalf of investors of Atea Pharmaceuticals, Inc. (Atea or the Company) (NASDAQ:AVIR). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Jan 7, 2022
01:02PM EST  Atea Pharma Highlights 2022 Strategic Priorities   Benzinga
07:00AM EST  COVID-19 Planning global Phase 2 outpatient trial for bemnifosbuvir (AT-527) designed to support anticipated combination trials   GlobeNewswire Inc
Jan 6, 2022
10:14AM EST  Expert Ratings For Atea Pharmaceuticals   Benzinga
10:06AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022   Benzinga
08:18AM EST  Morgan Stanley Downgrades Atea Pharmaceuticals to Underweight, Lowers Price Target to $7   Benzinga
Jan 3, 2022
07:00AM EST  Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 8:15 a.m. ET.   GlobeNewswire Inc
Dec 17, 2021
07:18AM EST  Atea Pharma Reports Will Be Added To Nasdaq Biotech Index, Effective Monday, Dec. 20, 2021   Benzinga
07:00AM EST  Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company, today announced that the company has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.   GlobeNewswire Inc
Dec 15, 2021
08:03AM EST  The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO   Benzinga
07:59AM EST  After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial   Benzinga
Dec 14, 2021
04:31PM EST  Atea Pharmaceuticals Introduces New Strategic Clinical Development Program For AT-527 In COVID-19   Benzinga
04:30PM EST  Responding to the rapidly evolving SARS-CoV-2, emerging variants and changing treatment landscape, Atea is updating the development strategy for AT-527   GlobeNewswire Inc
Nov 30, 2021
04:53PM EST  Atea Pharmaceuticals Sponsored Study Titled 'Drug-drug Interaction Study of Digoxin and AT-527 (R07496998)' Posted To ClinicalTrials.gov; Study Not Yet Recruiting   Benzinga
Nov 24, 2021
04:23PM EST  Atea Pharma Filing Shows Registration For $200M Mixed Securities Shelf Offering   Benzinga
Nov 22, 2021
07:00AM EST  Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 3:05 p.m. ET.   GlobeNewswire Inc
Nov 18, 2021
11:39AM EST  What 5 Analyst Ratings Have To Say About Atea Pharmaceuticals   Benzinga
10:19AM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2021   Benzinga
06:23AM EST  SVB Leerink Downgrades Atea Pharmaceuticals to Market Perform, Announces $11 Price Target   Benzinga
Nov 17, 2021
07:53AM EST  The Daily Biotech Pulse: Atea Sinks On Termination Of Roche Contract, Pfizer CFO To Retire, GSK-Vir Bag $1B Contract To Supply COVID Antibody Treatment   Benzinga
Nov 16, 2021
04:33PM EST  Atea Pharmaceuticals Says Strategic Collaboration Pursuant To Which Was Jointly Developing AT-527 For Treatment Of COVID-19 With Roche Will Be Terminating   Benzinga
04:30PM EST  Atea Pharmaceuticals Provides Update on Strategic Collaboration   GlobeNewswire Inc
04:26PM EST  Atea Pharmaceuticals Shares Halted On Code News Pending   Benzinga
Nov 11, 2021
04:06PM EST  Atea Pharmaceuticals Q3 EPS $(0.34) Up From $(1.74) YoY, Sales $32.80M   Benzinga
04:01PM EST  Phase 3 MORNINGSKY Protocol Amendment to Include New Primary Endpoint, Refined Patient Population and Increased Dose, with Plan to Accelerate Completion of Enrollment   GlobeNewswire Inc
03:55AM EST  Earnings Scheduled For November 11, 2021   Benzinga
Nov 4, 2021
07:54AM EDT  Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, November 11, 2021 at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2021, and to provide a clinical and corporate update.   GlobeNewswire Inc
Oct 20, 2021
10:14AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2021   Benzinga
09:17AM EDT  SVB Leerink Maintains Outperform on Atea Pharmaceuticals, Lowers Price Target to $20   Benzinga
07:35AM EDT  10 Biggest Price Target Changes For Wednesday   Benzinga
06:24AM EDT  JP Morgan Downgrades Atea Pharmaceuticals to Neutral, Lowers Price Target to $16   Benzinga
Oct 19, 2021
02:35PM EDT  Mid-Afternoon Market Update: Dow Surges Over 100 Points; Harmony Biosciences Shares Spike Higher   Benzinga
12:11PM EDT  Mid-Day Market Update: Silver Surges 3%; Galera Therapeutics Shares Plunge   Benzinga
10:08AM EDT  Mid-Morning Market Update: Markets Open Higher; Johnson & Johnson Boosts FY21 Guidance   Benzinga
07:31AM EDT  Atea Pharmaceuticals Reports Results For Phase 2 MOONSONG Trial Evaluating AT-527 In The Outpatient Setting Did Not Meet The Primary Endpoint In The Overall Population Of Patients With Mild Or Moderate COVID-19   Benzinga
07:00AM EDT  Topline Phase 2 MOONSONG trial results did not meet the primary endpoint in the overall population of patients with mild or moderate COVID-19, who were mostly low-risk with mild symptoms   GlobeNewswire Inc
Oct 12, 2021
06:00AM EDT  Molnupiravir? Not So Fast. What About Tollovir? Here's Why You Should Know What That Means   Benzinga
Oct 7, 2021
07:00AM EDT  Atea Pharmaceuticals to Present Virology and Early Clinical Data   GlobeNewswire Inc
Oct 5, 2021
10:14AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2021   Benzinga
06:24AM EDT  Morgan Stanley Downgrades Atea Pharmaceuticals to Equal-Weight, Announces $55 Price Target   Benzinga
Oct 4, 2021
05:21AM EDT  The following are some of the stocks making big moves in Monday's pre-market trading (as of 5.00 A.M. EDT).   RTTNews
Oct 1, 2021
02:51PM EDT  Mid-Afternoon Market Update: Nasdaq Rises Over 100 Points; Biomerica Shares Spike Higher   Benzinga
12:47PM EDT  Mid-Day Market Update: Dow Surges 300 Points; Omeros Shares Plummet   Benzinga
12:06PM EDT  Shares of Atea Pharmaceuticals, Inc. (AVIR) are gaining over 15% on Friday morning despite no stock related news to drive the shares.   RTTNews
10:21AM EDT  Mid-Morning Market Update: Markets Mostly Higher; ISM Manufacturing Index Rises In September   Benzinga
Sep 30, 2021
11:28AM EDT  Atea Pharmaceuticals Option Alert: Oct 15 $45 Calls Sweep (13) near the Ask: 200 @ $1.801 vs 86 OI; Ref=$37.86   Benzinga
Sep 29, 2021
07:00AM EDT  Atea Pharmaceuticals to Present at Guggenheim 2nd Annual Vaccines   GlobeNewswire Inc
Sep 9, 2021
11:05AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021   Benzinga
06:46AM EDT  SVB Leerink Initiates Coverage On Atea Pharmaceuticals with Outperform Rating, Announces Price Target of $60   Benzinga
06:20AM EDT  Atea Pharmaceuticals Filed U.S. Patent Application #20210275563 'HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19'   Benzinga
Sep 7, 2021
07:00AM EDT  Atea Pharmaceuticals to Present at the Morgan Stanley 19th Annual   GlobeNewswire Inc
Aug 24, 2021
07:06AM EDT  Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752's Potent In Vitro and In Vivo Activity Against Dengue and Other Flaviviruses   Benzinga
07:00AM EDT  -- In vitro and in vivo data demonstrate favorable safety and potency against multiple dengue virus serotypes supporting ongoing clinical development of AT-752   GlobeNewswire Inc
Aug 18, 2021
07:37AM EDT  Morgan Stanley Maintains Overweight on Atea Pharmaceuticals, Raises Price Target to $37   Benzinga
Aug 13, 2021
06:36AM EDT  Atea Unveils Trial Amendments, New Data For COVID-19 Program   Benzinga
Aug 12, 2021
05:00PM EDT  Atea Pharmaceuticals Q2 EPS $0.02 Up From $(0.99) YoY   Benzinga
04:05PM EDT  Atea Pharmaceuticals Provides Clinical and Corporate Update and   GlobeNewswire Inc
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
04:14AM EDT  Earnings Scheduled For August 12, 2021   Benzinga
Aug 9, 2021
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Aug 5, 2021
07:00AM EDT  Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, August 12, 2021 at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2021, and to provide a clinical and corporate update.   GlobeNewswire Inc
Jul 12, 2021
07:01AM EDT  Atea Pharmaceuticals to Present at William Blair Biotech Focus   GlobeNewswire Inc
Jun 30, 2021
11:11AM EDT  Atea Pharma's AT-527 Rapidly Reduces Viral Load Levels In Hospitalized COVID-19 Patients   Benzinga
10:51AM EDT  Atea Pharmaceuticals shares were trading higher after the company announced interim results from its Phase 2 study of AT-527 showing "rapid and sustained antiviral activity against sars-cov-2 in patients with covid-19 in the hospitalized setting"   Benzinga
07:04AM EDT  Atea Pharmaceuticals Announces Interim Results From Phase 2 Study Of AT-527 Showing 'Rapid and Sustained Antiviral Activity Against SARS-CoV-2 in Patients with COVID-19 in the Hospitalized Setting'   Benzinga
07:00AM EDT  Phase 2 Interim Virology Results Indicate Rapid and Sustained Antiviral Activity Against SARS-CoV-2 in Patients with COVID-19 in the Hospitalized Setting   GlobeNewswire Inc
Jun 16, 2021
09:26AM EDT  Atea Pharma Secures AT-527-Related Milestone Payment Of $50M From Roche   Benzinga
07:18AM EDT  Atea Pharma Achieves AT-527 Development Milestone Under License Agreement With Roche   RTTNews
07:05AM EDT  Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche; Expects To Receive A Related Payment Of $50M   Benzinga
07:00AM EDT  Atea Pharmaceuticals Announces Achievement of AT-527 Development   GlobeNewswire Inc
Jun 15, 2021
07:00AM EDT  Atea Pharmaceuticals Appoints Claudio Avila, MB, BS, Ph.D., as   GlobeNewswire Inc
Jun 3, 2021
07:54AM EDT  Morgan Stanley Maintains Overweight on Atea Pharmaceuticals, Lowers Price Target to $35   Benzinga
May 26, 2021
07:00AM EDT  Atea Pharmaceuticals to Present at Jefferies Virtual Healthcare   GlobeNewswire Inc
May 20, 2021
07:00AM EDT  Atea Pharmaceuticals Appoints Jerome Adams, M.D., M.P.H., to Board   GlobeNewswire Inc
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 13, 2021
04:42PM EDT  Atea Pharmaceuticals Q1 EPS $0.34 Beats $0.16 Estimate, Sales $65.98M Beat $48.63M Estimate   Benzinga
04:05PM EDT  -- Global Phase 3 MORNINGSKY trial of AT-527 in the outpatient setting recently initiated for the treatment of COVID-19 -- Enrollment advancing in Phase 1a trial of AT-752; drug candidate being developed for the treatment of dengue fever   GlobeNewswire Inc
08:10AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use   Benzinga
04:15AM EDT  Earnings Scheduled For May 13, 2021   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 11, 2021
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 6, 2021
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
07:00AM EDT  Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, May 13, 2021 at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2021, and to provide a corporate update.   GlobeNewswire Inc
May 5, 2021
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
May 4, 2021
08:10AM EDT  The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data   Benzinga
Apr 29, 2021
06:44AM EDT  Atea Pharma Stock Is Trading Higher As AT-527 Study In COVID-19 Moves Forward With Dosing   Benzinga
02:00AM EDT  Atea Pharmaceuticals Announces First Patient Dosed in Global Phase   GlobeNewswire Inc
Apr 6, 2021
08:46AM EDT  Morgan Stanley Maintains Overweight on Atea Pharmaceuticals, Raises Price Target to $82   Benzinga
Mar 30, 2021
04:03PM EDT  Atea Pharmaceuticals Reports FY20 EPS $(0.51) Down From $(1.39) YoY, Sales $48.63M   Benzinga
04:01PM EDT  Atea Pharmaceuticals Reports Full Year 2020 Financial Results and   GlobeNewswire Inc
04:04AM EDT  Earnings Scheduled For March 30, 2021   Benzinga
Mar 23, 2021
01:05PM EDT  Pfizer Starts Early-Stage Study Of Oral Antiviral COVID-19 Drug   Benzinga
07:00AM EDT  Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Tuesday, March 30, 2021 at 4:30 p.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2020, and to provide a business overview.   GlobeNewswire Inc
Mar 6, 2021
07:00AM EST  High Lung Levels of Active Triphosphate Predicted with Oral AT-527 for COVID-19 Patients   GlobeNewswire Inc
Feb 19, 2021
08:34AM EST  Atea Pharmaceuticals In-Licenses AT-527 From Roche For The Treatment If COVID-19 In Japan; Financial Terms Not Disclosed   Benzinga
08:30AM EST  Atea Pharmaceuticals Announces Chugai In-License of AT-527 from   GlobeNewswire Inc
Feb 11, 2021
11:21AM EST  Stocks That Hit 52-Week Highs On Thursday   Benzinga
Feb 9, 2021
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
07:07AM EST  Additional Preclinical Data For Atea Pharma's COVID-19 Antiviral Drug Candidate, Highlighted In Online Manuscript   Benzinga
Feb 8, 2021
04:05PM EST  Atea Pharmaceuticals Announces The Publication Of Preclinical Data Highlighting The Potential Activity Of Its AT-527 Against Coronavirus   Benzinga
04:01PM EST  Atea Pharmaceuticals Announces Publication of Preclinical Data   GlobeNewswire Inc
Feb 5, 2021
07:44AM EST  The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street   Benzinga
Feb 4, 2021
07:22AM EST  The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs   Benzinga
07:06AM EST  Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient Setting   Benzinga
07:00AM EST  Atea Pharmaceuticals Announces First Patient Dosed in Phase 2   GlobeNewswire Inc
Feb 3, 2021
07:31AM EST  The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision   Benzinga
Jan 29, 2021
11:49AM EST  JP Morgan Maintains Overweight on Atea Pharmaceuticals, Raises Price Target to $66   Benzinga
07:45AM EST  The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO   Benzinga
Jan 28, 2021
08:03AM EST  The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO   Benzinga
Jan 21, 2021
08:05AM EST  The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping   Benzinga
Jan 19, 2021
07:00AM EST  Senior executives bring proven industry experience to leadership roles in regulatory affairs and communications   GlobeNewswire Inc
Jan 15, 2021
07:57AM EST  The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges   Benzinga
Jan 14, 2021
07:57AM EST  The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates   Benzinga
Jan 12, 2021
08:16AM EST  The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue   Benzinga
Jan 8, 2021
07:25AM EST  The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs   Benzinga
Jan 5, 2021
08:39AM EST  The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data   Benzinga
Dec 30, 2020
08:16AM EST  The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data   Benzinga
Dec 29, 2020
08:09AM EST  The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica   Benzinga
Dec 23, 2020
08:31AM EST  The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut   Benzinga
Dec 21, 2020
07:00AM EST  Atea Pharmaceuticals to Present at 39th Annual J.P. Morgan   GlobeNewswire Inc
Dec 18, 2020
08:00AM EST  Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company, today announced that it has been added to the Russell 2000 Index, effective December 21, 2020, as part of the index's quarterly initial public offering (IPO) additions.   GlobeNewswire Inc
Nov 25, 2020
09:52AM EST  Benzinga's Top Upgrades, Downgrades For November 25, 2020   Benzinga
09:46AM EST  Evercore ISI Group Initiates Coverage On Atea Pharmaceuticals with Outperform Rating   Benzinga
07:35AM EST  The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback   Benzinga
07:00AM EST  Atea Pharmaceuticals to Present at Evercore ISI 3rd Annual   GlobeNewswire Inc
Nov 24, 2020
09:51AM EST  Benzinga's Top Upgrades, Downgrades For November 24, 2020   Benzinga
08:21AM EST  JP Morgan Initiates Coverage On Atea Pharmaceuticals with Overweight Rating, Announces Price Target of $45   Benzinga
08:19AM EST  William Blair Initiates Coverage On Atea Pharmaceuticals with Outperform Rating   Benzinga
08:10AM EST  Morgan Stanley Initiates Coverage On Atea Pharmaceuticals with Overweight Rating, Announces Price Target of $49   Benzinga
Nov 12, 2020
04:28PM EST  Atea Pharma 13D Filing From Bain Capital Shows 5.8% Active Stake In Co.   Benzinga
Nov 10, 2020
08:40AM EST  The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies   Benzinga
Nov 6, 2020
08:00AM EST  Atea Pharmaceuticals Expands Board of Directors with Appointment   GlobeNewswire Inc
07:47AM EST  The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold   Benzinga
Nov 3, 2020
04:01PM EST  Atea Pharmaceuticals Announces Closing of Initial Public Offering   GlobeNewswire Inc
Oct 30, 2020
12:06PM EDT  Atea Pharmaceuticals Shares Open For Trade At $27.02; IPO Priced At $24/Share   Benzinga
08:53AM EDT  Atea Pharmaceuticals Shares Will Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT, IPO Priced At $24.00/Share   Benzinga
08:52AM EDT  IPOs Happening Today, Friday, Oct. 30, 2020: AVIR, CONXU, BHSEU, LU, NBA/U, SQZ   Benzinga
Oct 29, 2020
09:29PM EDT  Atea Pharmaceuticals Prices IPO Of 12.50 Mln Shares At $24.00/shr   RTTNews


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC